ARAF S214C

Araf s214c是一种非小细胞肺癌的复发性致癌突变。已证明在细胞系中对索拉非尼和曲美替尼具有敏感性。在一个包含这种突变的晚期肺腺癌的病例研究中，索拉非尼也获得了近乎完全的临床缓解。从研究和临床的角度来看，这一病例给变异带来了更多的兴趣。
ARAF S214C has been found to be a recurrent oncogenic mutation in non-small cell lung cancer. It has been shown to confer sensitivity to sorafenib and trametenib in cell lines. In a case study of advanced stage lung adenocarcinoma harboring this mutation, sorafenib also acheived near-complete clinical remission. This case has brought more interest to the variant from a research and clinical perspective.